公开(公告)号：US12090235B2

公开(公告)日：2024-09-17

申请号：US17277994

申请日：2019-09-20

Applicant: ModernaTX, Inc.

Inventor： Allen Horhota ,  Christopher Karl McLaughlin ,  Jessica Cheney ,  Ben Geldhof ,  Jeffrey Hrkach ,  Melissa J. Moore ,  Stephen G. Hoge

IPC: A61K9/16 ,  A61K9/51 ,  A61K45/06

CPC classification number: A61K9/5192 ,  A61K9/5123 ,  A61K9/5146 ,  A61K45/06

Abstract: The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and the produced LNP formulations thereof. The present disclosure also provides therapeutic and diagnostic uses related to the produced LNP formulations.

公开(公告)号：US12023371B2

公开(公告)日：2024-07-02

申请号：US17127435

申请日：2020-12-18

Applicant: ModernaTX, Inc.

Inventor： Tirtha Chakraborty ,  Stephane Bancel ,  Stephen G. Hoge ,  Atanu Roy ,  Antonin De Fougerolles ,  Noubar B. Afeyan

IPC: A61K39/00 ,  C12N15/67

CPC classification number: A61K39/00 ,  C12N15/67

Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.

公开(公告)号：US11027025B2

公开(公告)日：2021-06-08

申请号：US14903869

申请日：2014-07-11

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  Eric Yi-Chun Huang ,  Tirtha Chakraborty

IPC: A61K48/00 ,  C12N15/90 ,  C12N9/16 ,  C12N15/11

Abstract: The present invention relates to compositions comprising and methods of using synthetic polynucleotides, e.g., modified mRNA, encoding CRISPR related proteins including dCAS9 and synthetic sgRNAs targeting a gene of interest.

公开(公告)号：US10258698B2

公开(公告)日：2019-04-16

申请号：US14775773

申请日：2014-03-14

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  Örn Almarsson ,  David D. Hile ,  Ciarán Lawlor ,  John Podobinski ,  Staci Sabnis ,  Antonin de Fougerolles ,  Divakar Ramakrishnan ,  Kristy M. Wood

IPC: A61K48/00 ,  A61K31/7105 ,  C12Q1/68 ,  C12N15/87 ,  C12N15/88 ,  A61K47/52

Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

公开(公告)号：US10155029B2

公开(公告)日：2018-12-18

申请号：US15429532

申请日：2017-02-10

Applicant: ModernaTX, Inc.

Inventor： Tirtha Chakraborty ,  Stephane Bancel ,  Stephen G. Hoge ,  Atanu Roy ,  Antonin De Fougerolles ,  Noubar B. Afeyan

IPC: A61K39/00 ,  C12N15/67

Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.

公开(公告)号：US10072057B2

公开(公告)日：2018-09-11

申请号：US15656740

申请日：2017-07-21

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  William Joseph Issa ,  Edward John Miracco ,  Jennifer Nelson ,  John Reynders ,  Matthew Stanton

IPC: C07K14/535 ,  C12P19/34 ,  C07K14/505 ,  C12N9/00 ,  A61K48/00 ,  C12P21/02 ,  C12N9/02

CPC classification number: C07K14/535 ,  A61K48/005 ,  C07K14/505 ,  C12N9/0069 ,  C12P19/34 ,  C12P21/02 ,  C12Y113/12007

Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.

公开(公告)号：US11708396B2

公开(公告)日：2023-07-25

申请号：US17162061

申请日：2021-01-29

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  Tirtha Chakraborty ,  Joshua P. Frederick ,  Matthias John ,  Antonin De Fougerolles

IPC: A61K48/00 ,  C07K14/47 ,  C12N15/85 ,  C12N15/113 ,  A61K31/7105 ,  A61K31/711 ,  A61K38/00

CPC classification number: C07K14/47 ,  A61K31/711 ,  A61K31/7105 ,  A61K48/0058 ,  C12N15/113 ,  C12N15/85 ,  A61K38/00 ,  C12N2310/141

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of signal-sensor polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US11603399B2

公开(公告)日：2023-03-14

申请号：US15591820

申请日：2017-05-10

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  Eric Yi-Chun Huang ,  Tirtha Chakraborty ,  Sayda M. Elbashir

IPC: C07K14/76 ,  C12N15/67 ,  C07K14/50 ,  C07K14/535 ,  C07K14/59 ,  C07K14/605 ,  C07K14/61 ,  C07K14/765 ,  C07K16/00 ,  A61K48/00

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of long-lived polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US11344504B1

公开(公告)日：2022-05-31

申请号：US17352904

申请日：2021-06-21

Applicant: ModernaTX, Inc.

Inventor： Joshua P. Frederick ,  Ailin Bai ,  Vladimir Presnyak ,  Stephen G. Hoge ,  Kerry Benenato ,  Iain McFadyen ,  Ellalahewage Sathyajith Kumarasinghe ,  Susannah Hewitt

IPC: A61K38/20 ,  A61K9/51 ,  A61K48/00 ,  A61K38/17 ,  A61K9/00 ,  A61K39/39 ,  A61K45/06 ,  A61K9/127 ,  C07K14/54 ,  C07K14/545 ,  C07K14/705 ,  A61K31/7088 ,  A61K31/7115 ,  A61P35/00 ,  A61K39/395 ,  A61K39/00 ,  B82Y5/00 ,  C12N15/88

Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

公开(公告)号：US10973917B2

公开(公告)日：2021-04-13

申请号：US16457300

申请日：2019-06-28

Applicant: ModernaTX, Inc.

Inventor： Joshua P. Frederick ,  Susannah Hewitt ,  Ailin Bai ,  Stephen G. Hoge ,  Vladimir Presnyak ,  Iain McFadyen ,  Kerry Benenato ,  Ellalahewage Sathyajith Kumarasinghe

IPC: A61K48/00 ,  A61K39/395 ,  C07K14/54 ,  C07K14/705 ,  C07K16/28 ,  A61K39/39 ,  A61K45/06 ,  A61K31/713 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.